What treatment options would you provide a HER2+/HR+ patient with significant residual disease s/p TCHP if they go on to develop severe neuropathy following adjuvant T-DM1 therapy?
Patient had an initial tumor response to TCHP, but still had significant residual disease present, including positive lymph nodes and residual breast tumor.